
Novo Nordisk received more than just chocolate eggs this Easter.
Five large financial institutions raised their target prices for shares in the pharmaceutical company, with large UK bank Barclays setting the highest target price after an increase from DKK 750 (USD 109) to DKK 850 (USD 123) per share. Its recommendation remains ”overweight.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app